Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
81 hedge funds and large institutions have $333M invested in Bellicum Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 21 closing their positions.
354% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $2.59M
52% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 21
44% more capital invested
Capital invested by funds: $230M → $333M (+$102M)
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
2% less funds holding
Funds holding: 83 → 81 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$12.1M |
| 3 |
JP Morgan Chase
New York
|
+$11.3M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.61M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$10.6M |
| 2 |
Millennium Management
New York
|
-$10.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.59M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.35M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.91M |
BLCM Hedge Fund Activity: Q4 2015 in Review
81 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2015, worth a combined $333M — up 44% from $230M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BLCM and 19 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 32 added.
The largest buyer was Fidelity Investments, adding an estimated $16M. The largest seller was Citadel Advisors, cutting an estimated $10.6M.
- 81 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2015, down from 83 in Q3 2015.
- Funds reported $333M of Bellicum Pharmaceuticals, Inc. stock for Q4 2015, up 44% quarter-over-quarter.
- 19 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2015 and 21 closed out, a net change of -2 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2015 was Fidelity Investments, an estimated $16M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2015 was Citadel Advisors, an estimated $10.6M sold.
Based on aggregated 13F filings for Q4 2015.